【摘要】 乳腺癌新辅助治疗是指在手术前进行的全身药物治疗。人表皮生长因子受体2(HER2)阳性乳腺癌预后不良，新辅助治疗为HER2阳性乳腺癌的治疗提供了新型模式，已经彻底改变了其治疗方式和预后。目前曲妥珠单抗和帕妥珠单抗双重抗HER2靶向联合非蒽环类化疗是首选的较高病理完全缓解率（p CR）以及更好预后的新辅助方案之一。未来曲妥珠单抗联合小分子TKI药物，以及新的ADC类药物，免疫治疗联合靶向治疗等，结合可靠生物标志物后，将实现HER2阳性乳腺癌更为精准的治疗。本文就双靶时代的HER2阳性乳腺癌新辅助治疗进行简要综述，并对其未来发展方向进行展望。更多还原

【Abstract】 Neoadjuvant therapy is a preoperative systemic treatment for patients with breast cancer. This therapy has greatly improved the clinical outcomes of human epidermal growth factor receptor 2(HER2)-positive breast cancer, which is associated with poor prognosis. Currently, dual anti-HER2 antibodies,including trastuzumab and pertuzumab, combined with non-anthracycline chemotherapy is one of the standard regimens to achieve high pathologic complete response rate and satisfactory efficacy. The combination of trastuzumab with tyrosine kinase inhibitors, antibody-drug conjugate drugs, or immunotherapy combined with target therapy, under the indications of reasonable biomarkers, is effective for HER2-positive breast cancer. In this article, we briefly reviewed neoadjuvant therapy in the dual-targeting therapy era and discussed its future perspectives.更多还原